Rutstein Sarah E, Limarzi-Klyn Laura, Chen Jane S, Agyei Yaw O, Ahmed Shahnaz, Bell Ian, Cohen Myron, Fogel Jessica M, Go Vivian, Haines Dan, Hamilton Erica L, Hoffman Irving F, Hosseinipour Mina C, Marzinke Mark A, Miller William C, Mukatipa Mathews, Pulerwitz Julie, Spiegel Hans M L, Ye Ting, Matoga Mitch
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
JMIR Res Protoc. 2025 Jun 18;14:e72981. doi: 10.2196/72981.
BACKGROUND: Preexposure prophylaxis (PrEP) remains one of the most efficacious interventions for preventing HIV, but its effectiveness is often limited by poor persistence. Although regional efforts have primarily focused on young women and men who have sex with men, heterosexual men in East and Southern Africa represent a crucial group to engage and retain in PrEP care-both to improve health outcomes for men and to interrupt HIV transmission chains. Men seeking sexually transmitted infection (STI) services are particularly vulnerable to HIV acquisition, yet only a few interventions have tested strategies for engaging and retaining these men in PrEP services. Systems navigation, which addresses barriers to health care access and enhances comfort in clinical settings, may offer a promising approach to improving persistent PrEP use among heterosexual men. OBJECTIVE: This study will assess the effect of a peer-delivered systems navigator-facilitated HIV prevention package on PrEP persistence at 26 weeks among heterosexual men seeking STI clinical services in Lilongwe, Malawi. It will also evaluate the acceptability of the intervention and barriers to implementation among key stakeholders. Insights will inform the feasibility of a future randomized controlled trial. METHODS: In this single-site pilot type I effectiveness-implementation hybrid randomized controlled trial, 200 heterosexual men seeking STI services and initiated on PrEP in Lilongwe, Malawi, will be randomized (1:2) to standard-of-care PrEP services or systems navigator-assisted PrEP care (intervention). Participants will be followed every 13 weeks for at least 26 and up to 52 weeks. PrEP use and engagement in care will be assessed through medical record review and intraerythrocytic tenofovir diphosphate measurement, using objective biomedical analyses via dried blood spot. Primary effectiveness and implementation outcomes include 26-week PrEP persistence (adapted to accommodate daily oral, event-driven oral, or injectable PrEP) and acceptability, respectively. Additional implementation outcomes include feasibility and cost. Exploratory objectives characterize preferences for PrEP modalities, perceived and experienced stigma, and the influence of gender norms on PrEP persistence. All clinical services, including the provision of PrEP and PrEP safety monitoring, are being conducted by the Malawi Ministry of Health. RESULTS: HPTN (HIV Prevention Trials Network) 112 was funded in November 2023. Study recruitment began in April 2024 and closed in November 2024. As of February 3, 2025, the study has enrolled 199 participants, with follow-up expected through June 2025. No interim analyses were planned; data analysis for primary end points is expected in the summer of 2025. CONCLUSIONS: Improving PrEP use outcomes among heterosexual men in East and Southern Africa is critical to interrupting HIV transmission. This study offers unique insights into a low-resource, potentially scalable intervention, focusing on a group of men at particularly high risk of HIV acquisition-those with recent STIs. The hybrid RCT design addresses clinically relevant effectiveness questions and explores key determinants that will inform future multisite implementation trials. TRIAL REGISTRATION: ClinicalTrials.gov NCT06200545; https://clinicaltrials.gov/study/NCT06200545. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/72981.
背景:暴露前预防(PrEP)仍然是预防艾滋病毒最有效的干预措施之一,但其效果往往因依从性差而受到限制。尽管区域努力主要集中在年轻女性和男男性行为者身上,但东非和南部非洲的异性恋男性是参与并坚持接受PrEP治疗的关键群体——这既能改善男性的健康状况,又能中断艾滋病毒传播链。寻求性传播感染(STI)服务的男性特别容易感染艾滋病毒,但只有少数干预措施测试了让这些男性参与并坚持接受PrEP服务的策略。系统导航能够解决获得医疗保健的障碍并提高在临床环境中的舒适度,可能为提高异性恋男性持续使用PrEP提供一种有前景的方法。 目的:本研究将评估由同伴提供的系统导航员辅助的艾滋病毒预防套餐对马拉维利隆圭寻求性传播感染临床服务的异性恋男性在26周时PrEP依从性的影响。它还将评估该干预措施的可接受性以及关键利益相关者实施过程中的障碍。研究结果将为未来随机对照试验的可行性提供参考。 方法:在这项单中心I型有效性-实施混合随机对照试验中,200名在马拉维利隆圭寻求性传播感染服务并开始接受PrEP治疗的异性恋男性将被随机分组(1:2),分别接受标准护理PrEP服务或系统导航员辅助的PrEP护理(干预措施)。参与者将每13周接受一次随访,至少随访26周,最长随访52周。通过病历审查和红细胞内替诺福韦二磷酸测量来评估PrEP的使用情况和护理参与度,使用干血斑进行客观的生物医学分析。主要的有效性和实施结果分别包括26周时的PrEP依从性(适用于每日口服、事件驱动口服或注射用PrEP)和可接受性。其他实施结果包括可行性和成本。探索性目标是确定对PrEP剂型的偏好、感知和经历的耻辱感,以及性别规范对PrEP依从性的影响。所有临床服务,包括PrEP的提供和PrEP安全性监测,均由马拉维卫生部进行。 结果:HPTN(艾滋病毒预防试验网络)112于2023年11月获得资助。研究招募于2024年4月开始,2024年11月结束。截至2025年2月3日,该研究已招募了199名参与者,预计随访至2025年6月。未计划进行中期分析;主要终点的数据分析预计在2025年夏季进行。 结论:提高东非和南部非洲异性恋男性的PrEP使用效果对于中断艾滋病毒传播至关重要。本研究为一种资源匮乏但可能具有可扩展性的干预措施提供了独特见解,该干预措施针对的是一组感染艾滋病毒风险特别高的男性——近期患有性传播感染的男性。混合随机对照试验设计解决了临床相关的有效性问题,并探索了关键决定因素,这将为未来的多中心实施试验提供参考。 试验注册:ClinicalTrials.gov NCT06200545;https://clinicaltrials.gov/study/NCT06200545。 国际注册报告识别码(IRRID):DERR1-10.2196/72981。
Cochrane Database Syst Rev. 2008-7-16
Cochrane Database Syst Rev. 2004
Cochrane Database Syst Rev. 2001
Cochrane Database Syst Rev. 2011-3-16
Cochrane Database Syst Rev. 2009-4-15
Cochrane Database Syst Rev. 2013-10-26
N Engl J Med. 2024-10-3
Int J Transgend Health. 2022-10-25